Scholarly Index
Michael A. Carducci
Johns Hopkins University; 53,802 total citations; 797 total publications; best world rank #40
Johns Hopkins University
53,802Total citations
797Total publications
104H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Prostate Cancer Treatment and Research | Lifetime | 40 | US 30 | 99.79 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 45 | US 26 | 99.52 |
| Cancer, Lipids, and Metabolism | Lifetime | 155 | US 84 | 99.25 |
| Renal cell carcinoma treatment | Lifetime | 132 | US 83 | 99.23 |
| Histone Deacetylase Inhibitors Research | Lifetime | 97 | US 67 | 98.90 |
| Hormonal and reproductive studies | Lifetime | 199 | US 102 | 98.75 |
| Cancer Treatment and Pharmacology | Lifetime | 332 | US 182 | 99.01 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 249 | US 136 | 99.19 |
| Bone health and treatments | Lifetime | 274 | US 134 | 98.62 |
| Protein Degradation and Inhibitors | Lifetime | 364 | US 201 | 97.19 |
| Renal and related cancers | Lifetime | 714 | US 361 | 96.89 |
| Multiple and Secondary Primary Cancers | Lifetime | 666 | US 282 | 93.94 |
| PARP inhibition in cancer therapy | Lifetime | 603 | US 274 | 93.69 |
| Prostate Cancer Treatment and Research | 2021-2025 | 298 | US 107 | 97.06 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 521 | US 132 | 90.88 |
| PARP inhibition in cancer therapy | 2021-2025 | 936 | US 330 | 78.47 |